CY1118702T1 - Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου - Google Patents

Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου

Info

Publication number
CY1118702T1
CY1118702T1 CY20171100124T CY171100124T CY1118702T1 CY 1118702 T1 CY1118702 T1 CY 1118702T1 CY 20171100124 T CY20171100124 T CY 20171100124T CY 171100124 T CY171100124 T CY 171100124T CY 1118702 T1 CY1118702 T1 CY 1118702T1
Authority
CY
Cyprus
Prior art keywords
glioblastoma
composition
gbm
volumes
cancer vaccine
Prior art date
Application number
CY20171100124T
Other languages
English (en)
Inventor
Oliver Schoor
Norbert Hilf
Toni Weinschenk
Claudia Trautwein
Steffen Walter
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CY1118702T1 publication Critical patent/CY1118702T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4634—Antigenic peptides; polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ανοσοθεραπευτικά πεπτίδια και τη χρήση τους στην ανοσοθεραπεία, και συγκεκριμένα στην ανοσοθεραπεία του καρκίνου. Η παρούσα εφεύρεση γνωστοποιεί ογκο-σχετιζόμενους πεπτιδικούς επιτόπους Τ-βοηθητικών κυττάρων, μεμονωμένους ή σε συνδυασμό με άλλα ογκο-σχετιζόμενα πεπτίδια, οι οποίοι λειτουργούν ως ενεργά φαρμακευτικά συστατικά συνθέσεων εμβολίων που διεγείρουν αντικαρκινικές ανοσοαπαντήσεις. Συγκεκριμένα, η σύνθεση των πεπτιδίων της παρούσας εφεύρεσης μπορεί να χρησιμοποιηθεί σε συνθέσεις εμβολίων για να επιφέρουν αντικαρκινικές ανοσοαπαντήσεις έναντι γλοιωμάτων.
CY20171100124T 2008-10-01 2017-01-26 Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου CY1118702T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20080017305 EP2172211B1 (en) 2008-10-01 2008-10-01 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
US10597008P 2008-10-16 2008-10-16
EP09778749.3A EP2331118B1 (en) 2008-10-01 2009-09-28 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
PCT/EP2009/006979 WO2010037513A1 (en) 2008-10-01 2009-09-28 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers

Publications (1)

Publication Number Publication Date
CY1118702T1 true CY1118702T1 (el) 2017-07-12

Family

ID=40342382

Family Applications (11)

Application Number Title Priority Date Filing Date
CY20151100139T CY1116302T1 (el) 2008-10-01 2015-02-12 Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου
CY20161100759T CY1119744T1 (el) 2008-10-01 2016-08-02 Μια συνθεση που αποτελειται απο ογκο-σχετιζομενα πεπτιδια και ενα εμβολιο για την θεραπεια του γλοιοβλαστωματος και αλλων καρκινων
CY20171100124T CY1118702T1 (el) 2008-10-01 2017-01-26 Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου
CY181101403T CY1121098T1 (el) 2008-10-01 2018-12-28 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY20191100182T CY1121258T1 (el) 2008-10-01 2019-02-12 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY20201100073T CY1122677T1 (el) 2008-10-01 2020-01-28 Καινοτομος ανοσοθεραπεια εναντι ορισμενων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου
CY20201100449T CY1122913T1 (el) 2008-10-01 2020-05-15 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων των νευρωνων και του εγκεφαλου
CY20201100594T CY1123089T1 (el) 2008-10-01 2020-06-26 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY20201100606T CY1123098T1 (el) 2008-10-01 2020-06-30 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου
CY20201100613T CY1123113T1 (el) 2008-10-01 2020-07-03 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων των νευρωνων και του εγκεφαλου
CY20201100984T CY1123526T1 (el) 2008-10-01 2020-10-19 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20151100139T CY1116302T1 (el) 2008-10-01 2015-02-12 Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου
CY20161100759T CY1119744T1 (el) 2008-10-01 2016-08-02 Μια συνθεση που αποτελειται απο ογκο-σχετιζομενα πεπτιδια και ενα εμβολιο για την θεραπεια του γλοιοβλαστωματος και αλλων καρκινων

Family Applications After (8)

Application Number Title Priority Date Filing Date
CY181101403T CY1121098T1 (el) 2008-10-01 2018-12-28 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY20191100182T CY1121258T1 (el) 2008-10-01 2019-02-12 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY20201100073T CY1122677T1 (el) 2008-10-01 2020-01-28 Καινοτομος ανοσοθεραπεια εναντι ορισμενων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου
CY20201100449T CY1122913T1 (el) 2008-10-01 2020-05-15 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων των νευρωνων και του εγκεφαλου
CY20201100594T CY1123089T1 (el) 2008-10-01 2020-06-26 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY20201100606T CY1123098T1 (el) 2008-10-01 2020-06-30 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου
CY20201100613T CY1123113T1 (el) 2008-10-01 2020-07-03 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων των νευρωνων και του εγκεφαλου
CY20201100984T CY1123526T1 (el) 2008-10-01 2020-10-19 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου

Country Status (25)

Country Link
US (19) US8318677B2 (el)
EP (12) EP2172211B1 (el)
JP (10) JP5753783B2 (el)
KR (6) KR102392070B1 (el)
CN (3) CN102170900B (el)
AU (2) AU2009300088B2 (el)
BR (2) BRPI0920791B8 (el)
CA (9) CA2936920C (el)
CY (11) CY1116302T1 (el)
DK (12) DK2172211T3 (el)
EA (3) EA023378B1 (el)
ES (12) ES2536465T3 (el)
HK (2) HK1159526A1 (el)
HR (12) HRP20201025T8 (el)
HU (11) HUE031030T2 (el)
LT (10) LT2172212T (el)
MX (3) MX2011003540A (el)
NZ (4) NZ591882A (el)
PL (12) PL2172211T3 (el)
PT (12) PT2172211E (el)
RS (12) RS53782B1 (el)
SI (12) SI2172211T1 (el)
TR (2) TR201900852T4 (el)
UA (3) UA103202C2 (el)
WO (2) WO2010037514A2 (el)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435507B2 (en) 2004-08-19 2013-05-07 University Of Maryland Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
PT2183361E (pt) * 2007-07-27 2015-09-11 Immatics Biotechnologies Gmbh Nova imunoterapia para tumores neuronais e cerebrais
EP2113253B1 (en) * 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
NO2119726T3 (el) * 2008-05-14 2015-05-23
RS53782B1 (en) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh TUMOR-ASSOCIATED PEPTIDES PREPARED AND ANTI-CHANGE RESPONSE FOR GLIOBLASTOMA (GBM) AND OTHER CANCER TREATMENTS
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
AU2015200751B2 (en) * 2010-03-19 2016-11-10 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
EP3511013B1 (en) * 2010-08-24 2022-09-07 University of Pittsburgh - Of the Commonwealth System of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US20140017266A1 (en) * 2010-12-03 2014-01-16 The Government Of The United States, As Represented By The Secretary Of Hhs, Nih Anti-podoplanin antibodies and methods of use
SG191154A1 (en) * 2010-12-14 2013-07-31 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
US20140154269A1 (en) * 2011-04-26 2014-06-05 The Methodist Hospital Research Institute Targeted nanovectors and their use for treatment of brain tumors
CA2847698C (en) * 2011-09-14 2020-09-01 Northwestern University Nanoconjugates able to cross the blood-brain barrier
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
MX367614B (es) 2012-01-20 2019-08-28 Del Mar Pharmaceuticals Uso de hexitoles sustituidos que incluyen dianhidrogalactitol y analogos para tratar enfermedad neoplasica y celulas madre de cancer que incluyen glioblastoma multiforme y meduloblastoma.
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
WO2013173411A1 (en) 2012-05-16 2013-11-21 Stemline Therapeutics, Inc Cancer stem cell targeted cancer vaccines
CN112587658A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
TWI776192B (zh) * 2013-08-05 2022-09-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（四）
HUE057334T2 (hu) 2013-08-05 2022-05-28 Immatics Biotechnologies Gmbh Új immunterápia többféle tumor, például tüdõrák ellen, az NSCLC-t is beleértve
MX2019013161A (es) * 2013-11-04 2020-02-03 Immatics Biotechnologies Gmbh Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
CN104698059B (zh) * 2013-12-04 2017-07-21 苏州中赢医疗科技有限公司 一种脑胶质瘤肿瘤标志物及其应用
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
KR101503341B1 (ko) * 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
PL3689899T3 (pl) 2014-04-25 2022-01-31 2Seventy Bio, Inc. Chimeryczne receptory antygenowe promotora mnd
JP6613526B2 (ja) * 2014-05-28 2019-12-04 学校法人東京女子医科大学 膠芽腫の予測方法
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
AU2015269197B2 (en) 2014-06-06 2018-10-04 2Seventy Bio, Inc. Improved T cell compositions
JP6366379B2 (ja) * 2014-06-20 2018-08-01 キヤノン株式会社 被検体情報取得装置
NZ728555A (en) 2014-07-24 2024-07-26 2Seventy Bio Inc Bcma chimeric antigen receptors
JP6474893B2 (ja) * 2014-11-06 2019-02-27 オーエスイー・イミュノセラピューティクス 脳転移の処置のための治療用マルチペプチドｔ特異的免疫療法
ES2895640T3 (es) 2014-12-12 2022-02-22 2Seventy Bio Inc Receptores de antígenos quiméricos de BCMA
MA48487B1 (fr) * 2014-12-23 2021-11-30 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
JP6985153B2 (ja) * 2015-05-06 2021-12-22 イマティクス バイオテクノロジーズ ゲーエムベーハー 結腸直腸がん（ｃｒｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチドとそのスキャフォールドとの組み合わせ
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
WO2016200787A2 (en) 2015-06-09 2016-12-15 The Board Of Regents Of The University Of Oklahoma Compositions and treatments for haemophilus influenzae
EP3319635B1 (en) 2015-06-24 2021-04-21 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
EP3919507A3 (en) 2015-07-01 2022-01-12 Immatics Biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PL3319985T3 (pl) * 2015-07-06 2021-05-04 Immatics Biotechnologies Gmbh Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem raka przełyku i innych rodzajów raka
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
TWI782433B (zh) 2015-08-28 2022-11-01 德商英麥提克生物技術股份有限公司 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
US10709758B2 (en) 2015-09-03 2020-07-14 The Board Of Regents Of The University Of Oklahoma Peptide inhibitors of clostridium difficile toxin B (TcdB) toxin
CN108289909A (zh) 2015-10-19 2018-07-17 巴尔的摩马里兰大学 用于产生工程改造的人原代血液树突细胞系的方法
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
US10604759B2 (en) 2016-01-15 2020-03-31 City Of Hope Targeting glioblastoma stem cells through the TLX-TET3 axis
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
CN105664134B (zh) * 2016-03-13 2019-04-26 浙江药苑生物科技有限公司 一种用于治疗骨癌的药物组合物
PT3430037T (pt) 2016-03-16 2022-11-23 Immatics Biotechnologies Gmbh Células t transfetadas e recetores de células t para uso em imunoterapia anticancro
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
GB201604490D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
SG11201808627RA (en) * 2016-04-06 2018-10-30 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR101881300B1 (ko) 2016-06-30 2018-07-25 영남대학교 산학협력단 아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법
ES2950435T3 (es) * 2016-10-03 2023-10-10 Ottawa Hospital Res Inst Composiciones y métodos para mejorar el crecimiento, la propagación y la eficacia oncolítica e inmunoterapéutica de virus oncolíticos de ARN
KR20190082241A (ko) 2016-11-04 2019-07-09 블루버드 바이오, 인코포레이티드. 항-bcma car t 세포 조성물
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
AU2017379900A1 (en) * 2016-12-22 2019-06-13 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN112210010B (zh) 2017-01-06 2023-12-05 优特力克斯有限公司 抗-人4-1bb抗体及其应用
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
WO2018160498A1 (en) * 2017-02-28 2018-09-07 Lyten, Inc. Mixed allotrope particulate carbon films and carbon fiber mats
BR112019023477A2 (pt) * 2017-05-08 2020-06-30 Gritstone Oncology, Inc. vetores de neoantígeno de alfavírus
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用
CN107034305A (zh) * 2017-06-19 2017-08-11 上海市第十人民医院 恶性胶质瘤的一种诊断标志物
EP3694532A4 (en) 2017-10-10 2021-07-14 Gritstone Oncology, Inc. IDENTIFICATION OF NEOANTIGENS BY MEANS OF HOT SPOTS
JP2021503897A (ja) 2017-11-22 2021-02-15 グリットストーン オンコロジー インコーポレイテッド 新生抗原のためのジャンクションエピトープ提示の低減
EP3725092A4 (en) 2017-12-14 2021-09-22 FloDesign Sonics, Inc. DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER
WO2019118793A2 (en) * 2017-12-14 2019-06-20 Ezy Biotech Llc Subject-specific tumor inhibiting cells and the use thereof
FI3773689T3 (fi) * 2018-04-11 2023-01-31 Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
CN108715832B (zh) * 2018-06-01 2020-11-10 段海峰 一种抑制肿瘤生长的间充质干细胞及制备方法和应用
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
RU2706554C1 (ru) * 2018-12-13 2019-11-19 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов
CN109796536B (zh) * 2019-02-22 2021-09-17 上海尚泰生物技术有限公司 一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
GB2599510B (en) * 2019-04-05 2023-08-30 Earli Inc Improved methods and compositions for synthetic biomarkers
US10937541B2 (en) 2019-05-28 2021-03-02 PAIGE.AI, Inc. Systems and methods for processing images to prepare slides for processed images for digital pathology
JP7457733B2 (ja) 2019-05-30 2024-03-28 グリットストーン バイオ インコーポレイテッド 改変アデノウイルス
CN110579457B (zh) * 2019-09-20 2021-11-02 郑州大学第一附属医院 波形蛋白特异响应性荧光探针及其制备方法和应用
CN112824427B (zh) * 2019-11-18 2022-06-24 杨小骏 一种抑制胶质瘤的短肽及其应用
CN113318225B (zh) * 2020-02-28 2024-01-19 无锡派列博生物医药科技有限公司 肿瘤免疫增强剂及其制法和应用
CN113621025A (zh) * 2020-03-18 2021-11-09 北京鼎成肽源生物技术有限公司 一种乳腺癌靶标抗原、乳腺癌靶标抗原刺激培养的ctl细胞及其应用
CN115552017A (zh) * 2020-03-31 2022-12-30 步行鱼治疗学公司 经修饰的b细胞及其使用方法
EP4127188A4 (en) 2020-03-31 2024-08-21 Walking Fish Therapeutics MODIFIED B CELLS AND METHODS OF USE THEREOF
IL300026A (en) 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes
KR102711471B1 (ko) 2020-08-14 2024-09-30 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2022047248A1 (en) * 2020-08-28 2022-03-03 Torigen Pharmaceuticals, Inc. Immune memory enhanced preparations and uses thereof
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2023192820A2 (en) * 2022-03-30 2023-10-05 Iogenetics, Llc Tumor-associated antigens in brain tumors
PL441229A1 (pl) * 2022-05-19 2023-11-20 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
ES487106A0 (es) 1978-12-22 1981-05-16 Biogen Nv Un metodo para producir al menos un polipeptido que muestra antigenicidad de hbv
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5338839A (en) * 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
KR100235089B1 (en) 1992-05-14 1999-12-15 Mitsui Chemicals Inc Ptp or blister packaging articles and packaging material therefor
GB2267257A (en) 1992-05-14 1993-12-01 Ford Motor Co A vehicle load compartment liner.
AU678483B2 (en) 1993-06-03 1997-05-29 Protherics Inc. Antibody fragments in therapy
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
ATE244300T1 (de) 1996-01-17 2003-07-15 Imp College Innovations Ltd Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
TW575583B (en) * 1996-04-24 2004-02-11 Akzo Nobel Nv Novel peptides suitable for use in antigen specific immunosuppressive therapy
CA2262007A1 (en) * 1996-07-22 1998-01-29 The Rockefeller University Env-glycoprotein vaccine for protection of htlv-i and -ii infection
AU6240798A (en) 1997-01-15 1998-08-07 Zymogenetics Inc. Zppar6, human tailless nuclear hormone receptor (tlx receptor)
CA2243984A1 (en) * 1997-02-13 1998-08-20 Smithkline Beecham P.L.C. Neural cell adhesion molecule splicing variants
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1999028349A2 (en) * 1997-12-02 1999-06-10 Medarex, Inc. CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
US7258860B2 (en) * 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO1999055380A1 (en) * 1998-04-27 1999-11-04 Pacific Northwest Cancer Foundation Nr-CAM GENE, NUCLEIC ACIDS AND NUCLEIC ACID PRODUCTS FOR THERAPEUTIC AND DIAGNOSTIC USES FOR TUMORS
US20030082586A1 (en) * 1999-06-29 2003-05-01 Millennium Pharmaceuticals, Inc. Antibodies having diagnostic, preventive, therapeutic, and other uses
US20020042386A1 (en) * 2000-01-31 2002-04-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
CA2392450A1 (en) * 2000-01-31 2001-08-16 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP1317275A1 (de) * 2000-09-06 2003-06-11 Müller, Friederike Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1356048A2 (en) * 2000-12-04 2003-10-29 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1379879A2 (en) * 2000-12-08 2004-01-14 Oxford GlycoSciences (UK) Limited Diagnosis and treatment of alzheimer's disease
WO2002074237A2 (en) * 2001-03-19 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
CA2364106A1 (fr) * 2001-11-30 2003-05-30 Christopher Gillberg Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques
US6589642B1 (en) 2001-12-21 2003-07-08 Kloeckner Pentaplast Of America, Inc. Three part high moisture barrier for packages
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
JP2005533486A (ja) 2002-02-20 2005-11-10 ダイアックス、コープ Ｍｈｃ−ペプチド複合体結合リガンド
WO2004015390A2 (en) * 2002-08-09 2004-02-19 Applera Corporation Lung cancer target proteins and use thereof
JP4721633B2 (ja) * 2002-10-11 2011-07-13 財団法人癌研究会 血小板凝集促進活性を有する物質
AU2003298984A1 (en) * 2002-12-27 2004-08-23 Shenzhen Tsinghua Yuanxing Bio-Pharm Science And Technology Co., Ltd. Method of preparing a vaccine and anti-tumor vaccines
US7273980B2 (en) 2004-01-13 2007-09-25 Wardle Scott A Position and velocity transducer using a phonograph disc and turntable
US7655751B2 (en) * 2004-01-23 2010-02-02 Green Peptide Co., Ltd. Epidermal growth factor receptor-derived peptides
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006026569A2 (en) * 2004-08-27 2006-03-09 Northeastern University Comprehensive characterization of complex proteins at trace levels
PL1642905T3 (pl) * 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
CN101072875B (zh) * 2004-12-07 2011-05-18 东丽株式会社 新型癌抗原肽及其用途
KR100809410B1 (ko) * 2005-07-06 2008-03-05 주식회사 브레인가드 줄기세포 분화 유도용 조성물 및 그의 용도
DK1760089T3 (da) * 2005-09-05 2009-11-16 Immatics Biotechnologies Gmbh Tumor-associeret peptides bindende til human leukocyte antigen (HLA) class I eller II molecules og relateret anti-cancer vaccine
SI1760088T1 (sl) 2005-09-05 2008-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veže z različnimi molekulami humanega levkocitnega antigena (HLA) razreda II
WO2007047796A2 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
WO2007072494A1 (en) 2005-12-23 2007-06-28 Naik Praful Ramchandra Metallized packaging blister container
WO2008035350A1 (en) * 2006-09-21 2008-03-27 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
EP2084267B1 (en) * 2006-09-26 2018-04-11 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
EP2164859A4 (en) * 2007-03-06 2012-06-06 Iterative Therapeutics Inc METHODS AND COMPOSITIONS USING POLYMERIC IMMUNOGLOBULIN HYBRID PROTEINS
US8747855B2 (en) * 2008-04-09 2014-06-10 Technion Research & Development Foundation Limited Anti human immunodeficiency antibodies and uses thereof
EP2113253B1 (en) * 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
KR101184869B1 (ko) * 2008-04-24 2012-09-20 이매틱스 바이오테크놀로지스 게엠베하 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
RS53782B1 (en) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh TUMOR-ASSOCIATED PEPTIDES PREPARED AND ANTI-CHANGE RESPONSE FOR GLIOBLASTOMA (GBM) AND OTHER CANCER TREATMENTS
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
RS60625B1 (sr) * 2014-05-28 2020-09-30 Nono Inc Hloridna so tat-nr2b9c
CA3021159A1 (en) * 2016-04-21 2017-10-26 Immatics Biotechnologies Gmbh Immunotherapy against melanoma and other cancers
EP3679065A4 (en) * 2017-09-06 2021-05-19 California Institute of Technology SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR)

Also Published As

Publication number Publication date
WO2010037514A3 (en) 2010-06-03
KR20110074894A (ko) 2011-07-04
CA2936887C (en) 2019-11-12
US20190010190A1 (en) 2019-01-10
EP3069728B1 (en) 2018-11-14
EP3111952A1 (en) 2017-01-04
SI3132801T1 (sl) 2020-03-31
ES2770090T3 (es) 2020-06-30
US20170326217A1 (en) 2017-11-16
CA2936870A1 (en) 2010-04-08
US20160376315A1 (en) 2016-12-29
EP3124043A1 (en) 2017-02-01
EP2331118B1 (en) 2016-10-26
RS60381B1 (sr) 2020-07-31
JP2016145210A (ja) 2016-08-12
LT3124043T (lt) 2020-07-10
US20160376312A1 (en) 2016-12-29
PT3111952T (pt) 2019-02-05
WO2010037513A1 (en) 2010-04-08
EA023378B1 (ru) 2016-05-31
EA201100587A1 (ru) 2011-10-31
US20160355550A1 (en) 2016-12-08
US20210253637A1 (en) 2021-08-19
HRP20150223T8 (hr) 2015-07-03
PT2172211E (pt) 2015-03-09
LT3069728T (lt) 2019-02-11
EP3111952B1 (en) 2018-10-31
PL3120868T3 (pl) 2020-08-24
PT2331118T (pt) 2017-02-06
NZ591855A (en) 2012-11-30
EP2341927B1 (en) 2016-05-04
PL3124043T3 (pl) 2020-07-27
US9993540B2 (en) 2018-06-12
CA2936924C (en) 2019-07-16
EP3132801A1 (en) 2017-02-22
HRP20170115T1 (hr) 2017-03-24
HRP20190202T1 (hr) 2019-03-22
PL2172212T3 (pl) 2017-04-28
SI2172212T1 (sl) 2016-12-30
ES2584245T3 (es) 2016-09-26
KR102133402B1 (ko) 2020-07-14
DK3111952T3 (en) 2019-01-28
SI3124043T1 (sl) 2020-07-31
RS60386B1 (sr) 2020-07-31
KR20160103558A (ko) 2016-09-01
KR101883426B1 (ko) 2018-07-31
JP2017018101A (ja) 2017-01-26
CY1122913T1 (el) 2021-10-29
LT3120870T (lt) 2020-08-10
SI2172211T1 (sl) 2015-03-31
JP6367266B2 (ja) 2018-08-01
LT3111952T (lt) 2018-12-27
CY1123113T1 (el) 2021-10-29
LT3120869T (lt) 2020-11-10
DK2341927T3 (en) 2016-08-15
LT3120868T (lt) 2020-08-10
RS60006B1 (sr) 2020-04-30
RS60656B1 (sr) 2020-09-30
PL3120870T3 (pl) 2020-07-27
JP6150859B2 (ja) 2017-06-21
PT3120869T (pt) 2020-09-22
CN106986919A (zh) 2017-07-28
SI3120868T1 (sl) 2020-08-31
MX2011003539A (es) 2011-06-20
SI3120869T1 (sl) 2020-10-30
RS55531B1 (sr) 2017-05-31
LT2331118T (lt) 2016-12-27
KR102392070B1 (ko) 2022-04-29
CA2739384A1 (en) 2010-04-08
PT2172212T (pt) 2016-12-22
US20160376314A1 (en) 2016-12-29
KR20220058655A (ko) 2022-05-09
CA2936869C (en) 2019-08-06
DK2331118T3 (da) 2017-01-09
US10047123B2 (en) 2018-08-14
JP2012504393A (ja) 2012-02-23
JP5753783B2 (ja) 2015-07-22
BRPI0920759A2 (pt) 2016-03-08
TR201900852T4 (tr) 2019-02-21
JP2017023136A (ja) 2017-02-02
HUE049364T2 (hu) 2020-09-28
SI3111952T1 (sl) 2019-01-31
BRPI0920791A2 (pt) 2019-12-10
CA2936920A1 (en) 2010-04-08
LT2172212T (lt) 2016-11-10
HUE051030T2 (hu) 2021-01-28
ES2788129T8 (es) 2020-11-04
CY1121098T1 (el) 2019-12-11
US20160376317A1 (en) 2016-12-29
US20130004456A1 (en) 2013-01-03
CA2936868C (en) 2019-10-22
HUE047365T2 (hu) 2020-04-28
PL2341927T3 (pl) 2016-11-30
EP3120869A1 (en) 2017-01-25
US20210261614A1 (en) 2021-08-26
ES2802227T3 (es) 2021-01-18
HUE049367T2 (hu) 2020-09-28
HRP20201015T1 (hr) 2020-10-16
WO2010037514A2 (en) 2010-04-08
CY1119744T1 (el) 2018-06-27
HK1159526A1 (zh) 2012-08-03
CY1121258T1 (el) 2020-05-29
US10100085B2 (en) 2018-10-16
PT3069728T (pt) 2019-02-13
US10047124B2 (en) 2018-08-14
JP6297632B2 (ja) 2018-03-20
JP6214066B2 (ja) 2017-10-18
DK3120870T3 (da) 2020-06-22
HK1161106A1 (en) 2012-08-24
CN102170901A (zh) 2011-08-31
CA2936887A1 (en) 2010-04-08
ES2708654T3 (es) 2019-04-10
HRP20150223T1 (hr) 2015-06-05
SI3069728T1 (sl) 2019-03-29
CY1123098T1 (el) 2021-10-29
NZ591882A (en) 2012-12-21
DK2172211T3 (en) 2015-02-16
EA032437B1 (ru) 2019-05-31
EP2172212B1 (en) 2016-10-05
US10227381B2 (en) 2019-03-12
US10906936B2 (en) 2021-02-02
CN102170900A (zh) 2011-08-31
DK3132801T3 (da) 2020-02-10
US11208434B2 (en) 2021-12-28
CY1116302T1 (el) 2017-02-08
DK3124043T3 (da) 2020-05-04
DK3106175T3 (da) 2020-06-22
US8895514B2 (en) 2014-11-25
PL3132801T3 (pl) 2020-06-15
PT3120868T (pt) 2020-07-16
EP3120868B1 (en) 2020-04-08
PT3106175T (pt) 2020-07-01
PL3106175T3 (pl) 2020-08-24
ES2536465T3 (es) 2015-05-25
CA2739387A1 (en) 2010-04-08
JP6294913B2 (ja) 2018-03-14
DK2172212T3 (da) 2016-12-19
EP3120870B1 (en) 2020-04-01
BRPI0920791B8 (pt) 2022-02-15
US20150125478A1 (en) 2015-05-07
JP6294914B2 (ja) 2018-03-14
PT3132801T (pt) 2020-02-04
ES2710608T3 (es) 2019-04-26
HUE031030T2 (en) 2017-06-28
JP2017029135A (ja) 2017-02-09
PL3069728T3 (pl) 2019-05-31
PL3120869T3 (pl) 2021-01-25
EP3106175B1 (en) 2020-04-01
US8119139B2 (en) 2012-02-21
HRP20200722T1 (hr) 2020-10-16
EA201401104A1 (ru) 2015-05-29
EP3124043B1 (en) 2020-04-29
KR101687840B1 (ko) 2016-12-19
HRP20200110T1 (hr) 2020-05-15
HRP20182151T1 (hr) 2019-02-08
KR20180088494A (ko) 2018-08-03
AU2009300088A1 (en) 2010-04-08
EP3120870A1 (en) 2017-01-25
JP2017018102A (ja) 2017-01-26
RS60385B1 (sr) 2020-07-31
CN102170900B (zh) 2016-10-26
NZ624533A (en) 2015-09-25
CA2936920C (en) 2019-12-03
EP2341927A2 (en) 2011-07-13
LT3106175T (lt) 2020-08-10
US20160376313A1 (en) 2016-12-29
NZ603016A (en) 2014-05-30
CA2936870C (en) 2019-11-26
US20210238227A1 (en) 2021-08-05
HUE042115T2 (hu) 2019-06-28
AU2009300088B2 (en) 2014-09-04
EA201100586A1 (ru) 2011-10-31
RS53782B1 (en) 2015-06-30
SI2341927T1 (sl) 2016-08-31
UA125277C2 (uk) 2022-02-16
RS55043B1 (sr) 2016-12-30
HUE049366T2 (hu) 2020-09-28
CA2936924A1 (en) 2010-04-08
HUE050428T2 (hu) 2020-12-28
UA103202C2 (ru) 2013-09-25
SI3106175T1 (sl) 2020-08-31
CA2936982C (en) 2019-12-03
ES2802226T3 (es) 2021-01-18
PL2331118T3 (pl) 2017-05-31
HUE041446T2 (hu) 2019-05-28
US11136352B2 (en) 2021-10-05
CA2936982A1 (en) 2010-04-08
EP3132801B1 (en) 2019-10-30
ES2804723T3 (es) 2021-02-09
KR20110082155A (ko) 2011-07-18
HRP20201025T8 (hr) 2022-01-07
TR201900809T4 (tr) 2019-02-21
EP3069728A1 (en) 2016-09-21
US20130309193A1 (en) 2013-11-21
JP2014239681A (ja) 2014-12-25
PL2172211T3 (pl) 2015-05-29
JP2016047825A (ja) 2016-04-07
US20120141517A1 (en) 2012-06-07
DK2331118T5 (en) 2017-06-19
US20210347822A1 (en) 2021-11-11
ES2607460T3 (es) 2017-03-31
RS58443B1 (sr) 2019-04-30
US8318677B2 (en) 2012-11-27
HRP20200988T1 (hr) 2020-10-16
US10046037B2 (en) 2018-08-14
KR101756488B1 (ko) 2017-07-11
ES2612466T3 (es) 2017-05-17
CY1123089T1 (el) 2021-10-29
EP2172212A2 (en) 2010-04-07
CA2936869A1 (en) 2010-04-08
EP3106175A1 (en) 2016-12-21
CY1122677T1 (el) 2021-03-12
US20160376316A1 (en) 2016-12-29
CA2739384C (en) 2017-05-02
HRP20201228T1 (hr) 2021-02-05
CA2936868A1 (en) 2010-04-08
HRP20160915T1 (hr) 2016-10-07
JP5883476B2 (ja) 2016-03-15
AU2009300087A1 (en) 2010-04-08
US8961985B2 (en) 2015-02-24
JP2017000148A (ja) 2017-01-05
PT3124043T (pt) 2020-05-12
PT3120870T (pt) 2020-07-01
MX2011003540A (es) 2011-06-20
US20100158931A1 (en) 2010-06-24
RS58229B1 (sr) 2019-03-29
SI3120870T1 (sl) 2020-08-31
DK3120869T3 (da) 2020-08-10
ES2788129T3 (es) 2020-10-20
HRP20201025T1 (hr) 2020-12-25
LT3132801T (lt) 2020-02-10
US10919931B2 (en) 2021-02-16
EA023013B1 (ru) 2016-04-29
HRP20201015T8 (hr) 2022-01-21
RS60338B1 (sr) 2020-07-31
KR20200085381A (ko) 2020-07-14
CY1123526T1 (el) 2022-03-24
EP2172212A3 (en) 2010-04-14
MX338294B (es) 2016-04-11
DK3069728T3 (en) 2019-02-25
RS55543B1 (sr) 2017-05-31
PL3111952T3 (pl) 2019-04-30
CA2739387C (en) 2019-10-29
EP3120869B1 (en) 2020-07-22
HUE030296T2 (en) 2017-04-28
US10941181B2 (en) 2021-03-09
DK3120868T3 (da) 2020-06-22
EP2172211A1 (en) 2010-04-07
UA110599C2 (uk) 2016-01-25
EP3120868A1 (en) 2017-01-25
JP5855940B2 (ja) 2016-02-09
CN102170901B (zh) 2015-01-07
HUE029360T2 (en) 2017-02-28
US20110002963A1 (en) 2011-01-06
PT2341927T (pt) 2016-08-02
ES2819244T3 (es) 2021-04-15
AU2009300087B2 (en) 2014-09-04
JP2012504563A (ja) 2012-02-23
SI2331118T1 (sl) 2017-01-31
EP2331118A1 (en) 2011-06-15
BRPI0920791B1 (pt) 2022-01-18
HRP20161504T1 (hr) 2016-12-30
EP2172211B1 (en) 2014-12-03
US8653035B2 (en) 2014-02-18

Similar Documents

Publication Publication Date Title
CY1118702T1 (el) Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου
CY1119366T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενου του γαστρεντερικου και του γαστρικου καρκινου
CY1115999T1 (el) Νεα και ισχυρα mhc- κατηγοριας ιι πεπτιδια που προερχονται απο σουρβιβινη και νευροκανη
CY1123854T1 (el) Πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του καρκινου του προστατη και αλλων καρκινων
CY1123505T1 (el) Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του επιθηλιακου καρκινου των ωοθηκων και αλλων καρκινων
CY1124224T1 (el) Πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια κατα του καρκινου του μαστου και αλλων καρκινων
CY1123635T1 (el) Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του καρκινου των ωοθηκων και αλλων καρκινων
CL2020001987A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer. (divisional solicitud 201801532)
CY1121691T1 (el) Εξατομικευμενη ανοσοθεραπεια εναντι ογκων των νευρωνων και του εγκεφαλου
CY1117115T1 (el) Καινοτομος ανοσοθεραπεια εναντι ογκων και νευρωνων του εγκεφαλου
EA201300322A1 (ru) Композиция опухолеассоциированных пептидов и относящаяся к ним противораковая вакцина
CY1124950T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων, οπως του καρκινου του πνευμονα συμπεριλαμβανομενου του μμκπ
EA201891670A1 (ru) Пептиды, комбинации пептидов и медикаменты на клеточной основе для применения в иммунотерапии рака мочевого пузыря и других видов рака
EA201792484A1 (ru) Новые клеточные эпитопы и комбинации клеточных эпитопов для применения в иммунотерапии миеломы и других видов рака
EA201890635A1 (ru) Пептиды и комбинации пептидов для применения в иммунотерапии мелкоклеточного рака легких и других видов рака
EA201891701A1 (ru) Пептиды и комбинации пептидов для применения в иммунотерапии немелкоклеточного рака легких и других видов рака
EA201791150A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
CO7170127A2 (es) Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 m(lag-3) y usos de los mismos
EA201892159A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии омл и других видов рака
CY1124533T1 (el) Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του ηπατοκυτταρικου καρκινωματος (hcc) και αλλων καρκινων
CY1119253T1 (el) Καινοτομος ανοσοθεραπεια εναντι ογκων και νευρωνων του εγκεφαλου
CY1124038T1 (el) Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων και ικριωματων αυτων για χρηση στην ανοσοθεραπεια εναντι του ορθοκολικου καρκινου (crc) και αλλων καρκινων
CY1122083T1 (el) Καινοτομος ανοσοθεραπεια εναντι ορισμενων ογκων του αιματος, οπως της οξειας μυελογεους λευχαιμιας (ομλ)
CY1116819T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενου του γαστρεντερικου και γαστρικου καρκινου
CY1112212T1 (el) Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια